The global medical device manufacturer Intervascular has initiated a Post-Market Clinical Follow-Up (PMCF) registry to ensure the continued safety and efficacy of its advanced line of vascular grafts and patches. This development is significant for healthcare professionals, clinical researchers, and regulatory teams focused on managing vascular diseases.
With a range of devices targeting conditions like carotid artery diseases, aortic diseases, and peripheral arterial diseases, this registry will collect valuable post-market data to enhance product monitoring and align with EU MDR requirements.
- What changed?
- Who should take note?
- Study details and devices covered
- FAQ
- Conclusion and implications
- Disclaimer
What changed?
Intervascular’s PMCF registry is now actively recruiting across clinical sites. The initiative represents a proactive effort to adhere to European Union Medical Device Regulation (EU MDR), specifically Annex XIV requirements. By establishing this registry, Intervascular demonstrates its commitment to ongoing vigilance and transparent safety reporting well after the devices reach the market.
The PMCF aims to evaluate the clinical performance and safety of several collagen-coated vascular grafts and patches that are widely used in the treatment of vascular diseases.
Who should take note?
This announcement is relevant to multiple stakeholders:
- Clinical teams: To gain real-world insights into the use of vascular grafts for various arterial diseases.
- Regulatory affairs professionals: To observe how PMCF data aligns with regulatory expectations for Post-Market Surveillance (PMS).
- Healthcare providers: To understand the latest developments in vascular graft performance and patient safety.
Study details and devices covered
The registry will focus on a well-established portfolio of vascular grafts, which are designed to address the needs of patients with critical arterial conditions. Key devices include:
- Intergard Standard: Collagen-coated vascular grafts and patches.
- Hemashield: Another collagen-coated variant for vascular reconstruction.
- Intergard Silver: Antimicrobial, collagen-coated grafts incorporating silver to mitigate infection risks.
- Intergard Synergy: Advanced antimicrobial grafts offering dual protection.
The registry will collect real-world performance data under clinical-use conditions, as specified in regulatory guidelines. Recruitment is ongoing, with healthcare centers already participating globally. This is an important step toward identifying and quantifying any residual risks associated with long-term use.
These vascular grafts have been in use for conditions like critical limb ischemia and carotid artery stenosis. The PMCF allows Intervascular to assess the performance and gather clinical evidence for continuous product improvement.
FAQ
- What is the primary goal of this registry?
To monitor the clinical performance and safety of Intergard vascular grafts under post-market conditions.
- Who manages the registry?
Intervascular, the manufacturer of the listed vascular grafts, oversees the PMCF registry.
- What medical conditions are addressed?
Carotid artery diseases, aortic diseases, and peripheral arterial diseases.
- Where can I learn more about this study?
Visit the official ClinicalTrials.gov page at the link provided below.
Conclusion and implications
The launch of Intervascular’s PMCF registry is a crucial step in ensuring patient safety and compliance with EU MDR. This initiative not only adheres to stringent regulatory frameworks but also promotes enhanced clinical decision-making through robust post-market data collection.
Healthcare professionals and regulatory teams should monitor the registry updates to stay informed about any significant findings or necessary product adjustments.
Disclaimer
This article is intended for healthcare and regulatory professionals. It is informational in nature and should not be considered legal advice. For guidance, consult legal or regulatory experts.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07322913?term=medical+device